Vectura's Flutiform (fluticasone+formoterol) has failed in a phase 3 chronic obstructive pulmonary disease trial, preventing a filing in Europe. Development partner Mundipharma said that the trial did ...

The European Medicines Agency (EMA) has approved Flutiform pMDI for use in the treatment of children with asthma aged five years and over. The European Medicines Agency (EMA) has approved Flutiform ...

LONDON, UK, 20 April, 2012 - SkyePharma PLC (LSE SKP) today announces that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive ...

Weak Phase III data have dealt a blow to Vectura’s (LON:VEC) hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease (COPD) patients. Vectura shares fell as much as 10% ...

LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...

flutiform is the first pressurised metered-dose inhaler to combine the ICS, fluticasone propionate, with the fast-acting inhaled LABA, formoterol. 2 flutiform is licensed for asthma maintenance ...

SkyePharma says that its development and marketing partner Mundipharma has successfully completed a paediatric study with positive results on its flagship asthma combination drug Flutiform. SkyePharma ...

LONDON, Aug 21 (Reuters) - British drug delivery specialist SkyePharma trimmed first-half losses on lower revenue and said it remain confident about its key new lung drug Flutiform, despite a delay in ...

k-haler is an award-winning[3] breath-triggered aerosol device utilising a patented "kinked" valve - the k-valve(TM) which has been designed with the aim to make it easier for patients to use ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

Cambridge, UK, 16 April 2024 – Mundipharma and Vectura will now progress development of the reformulation of flutiform ® (fluticasone propionate/formoterol fumarate) following long-term collaboration, ...

LONDON, UK - SkyePharma PLC (LSE: SKP) today announces the launch of flutiform® in Germany by Mundipharma GmbH, an affiliate of the Group's development, marketing and distribution partner, Mundipharma ...